GoodRx vs Hims & Hers: Revenue Stagnation vs Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 hours ago
0mins
Should l Buy HIMS?
Source: Yahoo Finance
- GoodRx Revenue Trends: GoodRx reported a 4.4% year-over-year decline in Q1 2026 sales to $194 million, yet its Pharma Direct business saw an impressive 82% growth, contributing approximately 27% to total revenue, indicating potential amidst stagnation.
- Hims & Hers Growth Performance: Hims & Hers achieved a remarkable 59% year-over-year revenue increase in Q4 2025, reaching $617.8 million, alongside a 13% growth in subscribers, showcasing its strong market position and consumer appeal.
- Market Environment Impact: With the average annual cost of family health plans hitting $27,000 in 2026, fewer Americans have access to primary care, creating a robust tailwind for Hims & Hers' alternative platform, further driving its business growth.
- Investor Considerations: Despite GoodRx's revenue stagnation, the Motley Fool analyst team did not include it in their current top investment stocks list, reflecting a cautious market sentiment regarding its future performance, prompting investors to carefully assess its investment value.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise
12 Analyst Rating
3 Buy
6 Hold
3 Sell
Hold
Current: 25.650
Low
16.50
Averages
32.95
High
60.00
Current: 25.650
Low
16.50
Averages
32.95
High
60.00
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hims & Hers Health Q1 Earnings Announcement Scheduled
- Earnings Release Date: Hims & Hers Health (HIMS) is set to announce its Q1 earnings on May 11th after market close, with consensus EPS estimated at $0.13 and revenue projected at $616.85 million, reflecting a 5.3% year-over-year growth, indicating the company's ongoing revenue growth trajectory.
- Performance Forecast Analysis: Over the past year, HIMS has not missed EPS estimates, achieving a 100% beat on revenue expectations, showcasing strong revenue management capabilities, although EPS estimates have seen three downward revisions in the last three months.
- Market Reaction: Recent analysis suggests that Hims' stability could trigger a stock price rebound, particularly after J.P. Morgan upgraded its rating to Overweight, indicating increased market confidence in the company's future growth potential.
- Industry Dynamics Impact: The FDA's review of GLP-1 drugs may favor Hims, especially in competition with Novo Nordisk, potentially providing new market opportunities that could further drive the company's growth.
See More
GoodRx vs Hims & Hers: Revenue Stagnation vs Growth
- GoodRx Revenue Trends: GoodRx reported a 4.4% year-over-year decline in Q1 2026 sales to $194 million, yet its Pharma Direct business saw an impressive 82% growth, contributing approximately 27% to total revenue, indicating potential amidst stagnation.
- Hims & Hers Growth Performance: Hims & Hers achieved a remarkable 59% year-over-year revenue increase in Q4 2025, reaching $617.8 million, alongside a 13% growth in subscribers, showcasing its strong market position and consumer appeal.
- Market Environment Impact: With the average annual cost of family health plans hitting $27,000 in 2026, fewer Americans have access to primary care, creating a robust tailwind for Hims & Hers' alternative platform, further driving its business growth.
- Investor Considerations: Despite GoodRx's revenue stagnation, the Motley Fool analyst team did not include it in their current top investment stocks list, reflecting a cautious market sentiment regarding its future performance, prompting investors to carefully assess its investment value.
See More
FDA Leadership Shakeup May Impact Biotech Stocks
- Stock Price Surge: Following reports of potential dismissal of FDA Commissioner Marty Makary, shares of Replimune (REPL) and uniQure (QURE) surged by 17% and 15% respectively, indicating market optimism regarding regulatory improvements under new leadership.
- Industry Response: The pharmaceutical industry has expressed dissatisfaction with Makary's drug review policies, citing inconsistencies and overly restrictive processes that hinder innovative drug approvals, suggesting that new leadership could accelerate approval timelines and restore clearer regulatory guidance.
- Potential Beneficiaries: Companies like Replimune and uniQure, which have publicly clashed with the FDA, are seen as potential beneficiaries of new leadership, with Replimune's melanoma therapy RP1 being rejected and uniQure's Huntington's disease gene therapy AMT-130 facing significant shifts in review policy.
- Market Reaction: Despite REPL's stock falling approximately 50% over the past year, QURE's stock has risen by 124%, reflecting investor confidence in the future of the biotech sector and expectations for changes in FDA policies.
See More
Amazon Expands Access to Ozempic Medication
- Increased Market Competition: Amazon Pharmacy's launch of same-day delivery for Novo Nordisk's oral Ozempic directly challenges Hims' market position, resulting in a 5% drop in Hims' stock on Thursday, indicating heightened pressure in the GLP-1 market.
- Enhanced Medication Accessibility: Amazon announced that customers can access real-time medication availability, transparent pricing, and same-day delivery through its pharmacy, expected to cover nearly 3,000 cities and expand to 4,500 locations by year-end, significantly improving patient access to medications.
- AI Health Assistant Launch: Hims introduced Labs AI, an AI-based health assistant that analyzes up to 130 biomarkers and health trends, aimed at helping users better understand lab test results, thereby enhancing its competitive edge in health management.
- Uncertain Earnings Outlook: Hims' upcoming earnings report is expected to show quarterly revenue of $616.9 million, a year-over-year increase, but EBITDA is projected to decline to $45 million, reflecting challenges in profitability amid intensifying competition in the GLP-1 market.
See More
Three Stocks to Watch Under $50
- Insteel Performance Warning: Insteel (IIIN) trades at $26.14, with a mere 5.9% annual revenue growth over the past five years, lagging behind industry peers, indicating a potential decline in market competitiveness that could undermine investor confidence.
- Helix Energy Competitive Disadvantage: Helix Energy Solutions (HLX) is priced at $10.30, with a revenue base of $1.3 billion and a gross margin of only 11.4%, significantly lower than competitors, which restricts its investment capabilities in exploration and production, potentially leading to long-term growth challenges.
- Hims & Hers Growth Potential: Hims & Hers Health (HIMS) is priced at $27.43, boasting a customer growth rate of 29.5% over the past two years and a 16.9 percentage point increase in free cash flow margin, showcasing strong growth potential in the market that may attract more investor interest.
- Market Dynamics Analysis: Stocks priced between $10 and $50 often include mid-sized companies that typically carry lower risk; however, careful assessment of their growth potential and market competitiveness is essential to avoid investment pitfalls.
See More
Investor Sentiment Analysis in Healthcare Sector Shows Bearish Trends
- Bearish Sentiment in Biotech: As of May 2026, significant bearish bets have emerged in the biotechnology and telehealth sectors, with Hims & Hers Health showing a short interest of 31.78%, indicating investor concerns over clinical outcomes that could impact future funding and market confidence.
- Healthcare Sector Underperformance: Despite a 5.62% year-to-date rally in the S&P 500, the Health Care Select Sector SPDR® Fund (XLV) has declined by 6.23%, reflecting the sector's ongoing lag in 2026, which may prompt investors to reassess their portfolios.
- Short Interest Data: As of April 30, Tango Therapeutics and Acadia Healthcare have short interests of 27.90% and 24.07%, respectively, while Sarepta Therapeutics and Twist Bioscience are also close to 24%, indicating a pervasive bearish sentiment among mid- to mega-cap healthcare stocks.
- Low Short Stocks: In stark contrast to high short interest stocks, established companies like Johnson & Johnson (JNJ) and Eli Lilly (LLY) have minimal short interests of 0.82% and 0.91%, demonstrating the stability and investor confidence in mature firms within the sector.
See More
Hims & Hers Health Q1 Earnings Announcement Scheduled
- Earnings Release Date: Hims & Hers Health (HIMS) is set to announce its Q1 earnings on May 11th after market close, with consensus EPS estimated at $0.13 and revenue projected at $616.85 million, reflecting a 5.3% year-over-year growth, indicating the company's ongoing revenue growth trajectory.
- Performance Forecast Analysis: Over the past year, HIMS has not missed EPS estimates, achieving a 100% beat on revenue expectations, showcasing strong revenue management capabilities, although EPS estimates have seen three downward revisions in the last three months.
- Market Reaction: Recent analysis suggests that Hims' stability could trigger a stock price rebound, particularly after J.P. Morgan upgraded its rating to Overweight, indicating increased market confidence in the company's future growth potential.
- Industry Dynamics Impact: The FDA's review of GLP-1 drugs may favor Hims, especially in competition with Novo Nordisk, potentially providing new market opportunities that could further drive the company's growth.
See More
GoodRx vs Hims & Hers: Revenue Stagnation vs Growth
- GoodRx Revenue Trends: GoodRx reported a 4.4% year-over-year decline in Q1 2026 sales to $194 million, yet its Pharma Direct business saw an impressive 82% growth, contributing approximately 27% to total revenue, indicating potential amidst stagnation.
- Hims & Hers Growth Performance: Hims & Hers achieved a remarkable 59% year-over-year revenue increase in Q4 2025, reaching $617.8 million, alongside a 13% growth in subscribers, showcasing its strong market position and consumer appeal.
- Market Environment Impact: With the average annual cost of family health plans hitting $27,000 in 2026, fewer Americans have access to primary care, creating a robust tailwind for Hims & Hers' alternative platform, further driving its business growth.
- Investor Considerations: Despite GoodRx's revenue stagnation, the Motley Fool analyst team did not include it in their current top investment stocks list, reflecting a cautious market sentiment regarding its future performance, prompting investors to carefully assess its investment value.
See More
FDA Leadership Shakeup May Impact Biotech Stocks
- Stock Price Surge: Following reports of potential dismissal of FDA Commissioner Marty Makary, shares of Replimune (REPL) and uniQure (QURE) surged by 17% and 15% respectively, indicating market optimism regarding regulatory improvements under new leadership.
- Industry Response: The pharmaceutical industry has expressed dissatisfaction with Makary's drug review policies, citing inconsistencies and overly restrictive processes that hinder innovative drug approvals, suggesting that new leadership could accelerate approval timelines and restore clearer regulatory guidance.
- Potential Beneficiaries: Companies like Replimune and uniQure, which have publicly clashed with the FDA, are seen as potential beneficiaries of new leadership, with Replimune's melanoma therapy RP1 being rejected and uniQure's Huntington's disease gene therapy AMT-130 facing significant shifts in review policy.
- Market Reaction: Despite REPL's stock falling approximately 50% over the past year, QURE's stock has risen by 124%, reflecting investor confidence in the future of the biotech sector and expectations for changes in FDA policies.
See More
Amazon Expands Access to Ozempic Medication
- Increased Market Competition: Amazon Pharmacy's launch of same-day delivery for Novo Nordisk's oral Ozempic directly challenges Hims' market position, resulting in a 5% drop in Hims' stock on Thursday, indicating heightened pressure in the GLP-1 market.
- Enhanced Medication Accessibility: Amazon announced that customers can access real-time medication availability, transparent pricing, and same-day delivery through its pharmacy, expected to cover nearly 3,000 cities and expand to 4,500 locations by year-end, significantly improving patient access to medications.
- AI Health Assistant Launch: Hims introduced Labs AI, an AI-based health assistant that analyzes up to 130 biomarkers and health trends, aimed at helping users better understand lab test results, thereby enhancing its competitive edge in health management.
- Uncertain Earnings Outlook: Hims' upcoming earnings report is expected to show quarterly revenue of $616.9 million, a year-over-year increase, but EBITDA is projected to decline to $45 million, reflecting challenges in profitability amid intensifying competition in the GLP-1 market.
See More
Three Stocks to Watch Under $50
- Insteel Performance Warning: Insteel (IIIN) trades at $26.14, with a mere 5.9% annual revenue growth over the past five years, lagging behind industry peers, indicating a potential decline in market competitiveness that could undermine investor confidence.
- Helix Energy Competitive Disadvantage: Helix Energy Solutions (HLX) is priced at $10.30, with a revenue base of $1.3 billion and a gross margin of only 11.4%, significantly lower than competitors, which restricts its investment capabilities in exploration and production, potentially leading to long-term growth challenges.
- Hims & Hers Growth Potential: Hims & Hers Health (HIMS) is priced at $27.43, boasting a customer growth rate of 29.5% over the past two years and a 16.9 percentage point increase in free cash flow margin, showcasing strong growth potential in the market that may attract more investor interest.
- Market Dynamics Analysis: Stocks priced between $10 and $50 often include mid-sized companies that typically carry lower risk; however, careful assessment of their growth potential and market competitiveness is essential to avoid investment pitfalls.
See More
Investor Sentiment Analysis in Healthcare Sector Shows Bearish Trends
- Bearish Sentiment in Biotech: As of May 2026, significant bearish bets have emerged in the biotechnology and telehealth sectors, with Hims & Hers Health showing a short interest of 31.78%, indicating investor concerns over clinical outcomes that could impact future funding and market confidence.
- Healthcare Sector Underperformance: Despite a 5.62% year-to-date rally in the S&P 500, the Health Care Select Sector SPDR® Fund (XLV) has declined by 6.23%, reflecting the sector's ongoing lag in 2026, which may prompt investors to reassess their portfolios.
- Short Interest Data: As of April 30, Tango Therapeutics and Acadia Healthcare have short interests of 27.90% and 24.07%, respectively, while Sarepta Therapeutics and Twist Bioscience are also close to 24%, indicating a pervasive bearish sentiment among mid- to mega-cap healthcare stocks.
- Low Short Stocks: In stark contrast to high short interest stocks, established companies like Johnson & Johnson (JNJ) and Eli Lilly (LLY) have minimal short interests of 0.82% and 0.91%, demonstrating the stability and investor confidence in mature firms within the sector.
See More
